July 2022 - PsychedelicNewsWire (PNW)

FridayJul 29, 2022 12:03 pm

Research Finds Psychedelics May Open Door to Self-Actualization

According to Maslow’s Hierarchy of Needs, self-actualization is the realization of an individual's full potential and the complete development of their ability to enjoy and appreciate life. The highest level of psychological development, self-actualization, is only achievable once an individual have met their physiological, safety, belongingness, love and esteem needs. However, life tends to throw plenty of trials and tribulations that act as barriers to self-actualization, with Maslow estimating that just 1% of adults have self-actualized. Recent research into a federally controlled class of drugs has revealed an interesting fact: psychedelics have the ability to help people self-actualize. Individuals who…

ThursdayJul 28, 2022 11:26 am

DEA Sued Again for Denying Terminally Ill Patients Access to Psilocybin Therapy

The United States Drug Enforcement Administration (DEA) has been sued again for refusing to permit a doctor to treat patients with terminal illnesses using psilocybin therapy in accordance with state and federal Right To Try laws. Numerous trials have found that psilocybin, as well as MDMA, possess the potential to treat a range of mental health conditions, with the United States Food and Drug Administration (FDA) designating them as breakthrough therapies. Right To Try laws are aimed at increasing access to Schedule I investigational therapies that haven’t received approval for general use. The DEA is also facing political pressure from…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

WednesdayJul 27, 2022 1:02 pm

Measure to Legalize Psychedelics Qualifies for November Ballot in Colorado

Voters in the state of Colorado now have the chance to vote for the legalization of psychedelics after a measure advocated for by the Natural Medicine Colorado campaign was approved for the November ballot. This approval comes less than a month after activists in the state submitted an estimated 100,000 more signatures for the legalization initiative than was required for it to qualify for the ballot. In a press release, Kevin Matthews, one of the initiative’s designated representatives, stated that the group of activists were proud of the work done and argued that psychedelic medicines held great promise for individuals…

TuesdayJul 26, 2022 2:36 pm

Compass Pathways Appoints New CEO

Compass Pathways has announced that it will be replacing its chief executive officer by the end of the month. The company’s founder, CEO and chair, George Goldsmith, will be replaced as CEO by Kabir Nath, effective Aug. 1, 2022. The mental health company announced on its website that George Goldsmith will continue serving as executive chair from Aug. 1 to Dec. 31, 2022, to assist in the transition. Goldsmith will retain his position as the executive chair once the handover is complete. He cofounded Compass Pathways PLC (NASDAQ: CMPS) in 2016 and led the firm from a startup to a…

MondayJul 25, 2022 1:12 pm

What You Should Know, Do Before Investing in Psychedelics Stocks

With speculation about psychedelics at an all-time high and the market projected to grow exponentially in the next few years, psychedelic stocks have been a draw for many investors. However, given that the market is still new and has plenty of legal and regulatory challenges to surpass, investors interested in psychedelic stocks should exercise caution when investing their hard-earned cash. Most psychedelic companies are young with no record of success; many still have to go through long and costly clinical trials as well. This means that many of these fledgling companies are relying on debt to finance research and development.…

MondayJul 25, 2022 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

FridayJul 22, 2022 1:02 pm

A Review of Docuseries “How to Change Your Mind”

Last month, Netflix released the trailer for a docuseries called “How to Change Your Mind,” which was adapted from Michael Pollan’s book on the science of psychedelics and what it could teach us about depression, addiction, dying, consciousness and transcendence. Based on Pollan’s experiences and experiments with psychedelics, the docuseries was broken down into four 50-minute episodes with each focusing on a different psychedelic drug. The first episode discusses LSD while subsequent episodes cover psilocybin, MDMA and mescaline respectively. For plenty of people, Netflix’s new docuseries is the first time they are exposed to the growing world of psychedelic-assisted treatments.…

ThursdayJul 21, 2022 12:06 pm

Study Says Ayahuasca Users Tend to Exercise More, Eat Healthier

A new study has found that individuals who regularly use ayahuasca engage in a range of positive health behaviors that result in mental and physical health benefits. Ayahuasca is an entheogenic and psychedelic mixed brew that was traditionally used by the ancient Amazonian tribes in South America during religious ceremonies. In recent times, however, the brew has become popular due to its hallucinogenic effects and mental health benefits. Jose Carlos Bouso, the author of the study, stated that despite the growing popularity of the substances, some nations were prosecuting the use of ayahuasca. The study’s objective was to look into…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: July 2022